Click on image to view larger version.

Figure 1 Subject disposition. Subjects were assigned by random allocation to receive one of two sequences of treatment, either a two-way crossover (placebo, tadalafil) or a three-way crossover (placebo, tadalafil, ibutilide). The number of subjects assigned to each sequence of treatments (placebo-tadalafil, n = 32; placebo-tadalafil-ibutilide, n = 67) was sufficient to achieve the total number of subjects treated with both drugs for the three statistical drug pair comparisons specified by the prospective statistical analysis plan (total receiving: placebo vs. tadalafil = 90; tadalafil vs. ibutilide = 62; placebo vs. ibutilide = 61). Reasons for discontinuation are listed in the Results section. One subject received treatment with ibutilide and two treatments with placebo (rather than treatment with tadalafil and placebo). This subject was included in the intent-to-treat ibutilide-placebo, tadalafil-placebo, and tadalafil-ibutilide comparative analyses. *Not included in any of the comparative analyses because subjects did not receive at least two treatments.